Ascendis Pharma (ASND) reported a Q3 loss late Thursday of 1.72 euros ($1.81) per diluted share, narrower than a loss of 2.88 euros loss a year earlier.
Analysts polled by Capital IQ expected a loss of 1.46 euros.
Revenue for the quarter that ended Sept. 30 was 57.8 million euros, up from 48 million euros a year earlier.
Analysts surveyed by Capital IQ expected 70.3 million euros.
Shares of the company were about 8% lower in recent after-hours activity.
Price: 114.50, Change: -9.78, Percent Change: -7.87
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。